Catterall WA, Perez-Reyes E, Snutch TP,Striessnig J (16 de septiembre de 2019). «Voltage-gated calcium channels (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database». IUPHAR/BPS Guide to Pharmacology CITE (Edinburgh University Library) 2019 (4). ISSN2633-1020. doi:10.2218/gtopdb/f80/2019.4.
Adams DJ, Berecki G (July 2013). «Mechanisms of conotoxin inhibition of N-type (Ca(v)2.2) calcium channels». Biochimica et Biophysica Acta (BBA) - Biomembranes1828 (7): 1619-28. PMID23380425. doi:10.1016/j.bbamem.2013.01.019.
Molderings GJ, Likungu J, Göthert M (February 2000). «N-Type calcium channels control sympathetic neurotransmission in human heart atrium». Circulation101 (4): 403-7. PMID10653832. doi:10.1161/01.cir.101.4.403.
Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T (February 2007). «Ca2+ channel subtypes and pharmacology in the kidney». Circulation Research100 (3): 342-53. PMID17307972. doi:10.1161/01.RES.0000256155.31133.49.
Gorman KM, Meyer E, Grozeva D, Spinelli E, McTague A, Sanchis-Juan A, Carss KJ, Bryant E, Reich A, Schneider AL, Pressler RM, Simpson MA, Debelle GD, Wassmer E, Morton J, Sieciechowicz D, Jan-Kamsteeg E, Paciorkowski AR, King MD, Cross JH, Poduri A, Mefford HC, Scheffer IE, Haack TB, McCullagh G, Millichap JJ, Carvill GL, Clayton-Smith J, Maher ER, Raymond FL, Kurian MA (May 2019). «Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia». Am J Hum Genet104 (5): 948-956. PMC6507039. PMID30982612. doi:10.1016/j.ajhg.2019.03.005.
Adams, David J.; Berecki, Géza (1 de julio de 2013). «Mechanisms of conotoxin inhibition of N-type (Cav2.2) calcium channels». Biochimica et Biophysica Acta (BBA) - Biomembranes(en inglés)1828 (7): 1619-1628. ISSN0005-2736. PMID23380425. doi:10.1016/j.bbamem.2013.01.019.
Benjamin ER, Pruthi F, Olanrewaju S, Shan S, Hanway D, Liu X, Cerne R, Lavery D, Valenzano KJ, Woodward RM, Ilyin VI (September 2006). «Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR». Biochem Pharmacol72 (6): 770-82. PMID16844100. doi:10.1016/j.bcp.2006.06.003.
Bravo-Martínez J, Arenas I, Vivas O, Rebolledo-Antúnez S, Vázquez-García M, Larrazolo A, García DE (October 2012). «A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons». Exp Biol Med (Maywood)237 (10): 1209-18. PMID23045722. doi:10.1258/ebm.2012.012128.
Catterall WA, Perez-Reyes E, Snutch TP,Striessnig J (16 de septiembre de 2019). «Voltage-gated calcium channels (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database». IUPHAR/BPS Guide to Pharmacology CITE (Edinburgh University Library) 2019 (4). ISSN2633-1020. doi:10.2218/gtopdb/f80/2019.4.
Adams, David J.; Berecki, Géza (1 de julio de 2013). «Mechanisms of conotoxin inhibition of N-type (Cav2.2) calcium channels». Biochimica et Biophysica Acta (BBA) - Biomembranes(en inglés)1828 (7): 1619-1628. ISSN0005-2736. PMID23380425. doi:10.1016/j.bbamem.2013.01.019.
Adams DJ, Berecki G (July 2013). «Mechanisms of conotoxin inhibition of N-type (Ca(v)2.2) calcium channels». Biochimica et Biophysica Acta (BBA) - Biomembranes1828 (7): 1619-28. PMID23380425. doi:10.1016/j.bbamem.2013.01.019.
Molderings GJ, Likungu J, Göthert M (February 2000). «N-Type calcium channels control sympathetic neurotransmission in human heart atrium». Circulation101 (4): 403-7. PMID10653832. doi:10.1161/01.cir.101.4.403.
Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T (February 2007). «Ca2+ channel subtypes and pharmacology in the kidney». Circulation Research100 (3): 342-53. PMID17307972. doi:10.1161/01.RES.0000256155.31133.49.
Gorman KM, Meyer E, Grozeva D, Spinelli E, McTague A, Sanchis-Juan A, Carss KJ, Bryant E, Reich A, Schneider AL, Pressler RM, Simpson MA, Debelle GD, Wassmer E, Morton J, Sieciechowicz D, Jan-Kamsteeg E, Paciorkowski AR, King MD, Cross JH, Poduri A, Mefford HC, Scheffer IE, Haack TB, McCullagh G, Millichap JJ, Carvill GL, Clayton-Smith J, Maher ER, Raymond FL, Kurian MA (May 2019). «Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia». Am J Hum Genet104 (5): 948-956. PMC6507039. PMID30982612. doi:10.1016/j.ajhg.2019.03.005.
Adams, David J.; Berecki, Géza (1 de julio de 2013). «Mechanisms of conotoxin inhibition of N-type (Cav2.2) calcium channels». Biochimica et Biophysica Acta (BBA) - Biomembranes(en inglés)1828 (7): 1619-1628. ISSN0005-2736. PMID23380425. doi:10.1016/j.bbamem.2013.01.019.
Benjamin ER, Pruthi F, Olanrewaju S, Shan S, Hanway D, Liu X, Cerne R, Lavery D, Valenzano KJ, Woodward RM, Ilyin VI (September 2006). «Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR». Biochem Pharmacol72 (6): 770-82. PMID16844100. doi:10.1016/j.bcp.2006.06.003.
Bravo-Martínez J, Arenas I, Vivas O, Rebolledo-Antúnez S, Vázquez-García M, Larrazolo A, García DE (October 2012). «A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons». Exp Biol Med (Maywood)237 (10): 1209-18. PMID23045722. doi:10.1258/ebm.2012.012128.
uniprot.org
«UniProt». www.uniprot.org. Consultado el 24 de mayo de 2023.